# Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma

> **NCT01513187** · PHASE1,PHASE2 · COMPLETED · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 53 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib + interferon alpha 2A

## Key facts

- **NCT ID:** NCT01513187
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-11
- **Primary completion:** 2015-12
- **Final completion:** 2019-02-22
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513187, "Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01513187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*